EyePoint Inc

EyePoint CFO’s sell‑and‑rebuy of 5,000 shares reveals a portfolio‑restructuring move, not a negative signal. The strategy hints at insider confidence amid a 122% YTD stock rally.

EyePoint insider trades reveal short‑term tactics amid a growing retinal implant pipeline; see how these moves align with Phase III data, safety milestones, and future regulatory plans for EpiCure™ and gene therapy.

EyePoint Inc.’s CMO buys shares at $8.26 while selling options at no cost, signaling confidence in the company’s future drug‑device pipeline and potential upside from upcoming clinical and regulatory milestones.